Literature DB >> 16936438

Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension.

Shin-ichi Usui1, Atsushi Yao, Masaru Hatano, Osami Kohmoto, Toshiyuki Takahashi, Ryozo Nagai, Koichiro Kinugawa.   

Abstract

BACKGROUND: Left ventricular remodeling might be involved in the pathophysiology of right ventricular hypertrophy/failure due to pulmonary arterial hypertension (PAH), while the left ventricle is considered not under pressure/volume overload. METHODS AND
RESULTS: Rats with monocrotaline-induced PAH were used in the present study to examine whether upregulated neurohumoral factors may induce left ventricular (LV) remodeling and(/or) contribute to prognosis. Morphological analysis revealed a significant increase in the weight of the free walls of both ventricles and the interventricular septum, indicating biventricular hypertrophy, although systemic blood pressure was not elevated. RNase protection assay demonstrated the activation of a fetal gene program in the cardiac muscle of the left and right ventricular free walls. Similar activation of the fetal gene program was observed in the LV of rats continuously infused with angiotensin (AT) II, although this was not the case for rats infused with isoproterenol. Measured plasma levels of ATII, noradrenaline, and brain natriuretic peptide (BNP) were all significantly elevated in the PAH rats. Furthermore, the plasma BNP level positively correlated with the ratio of heart weight to body weight and the plasma level of ATII. Not right but LV hypertrophy was significantly reduced by treatment with an AT II type 1 receptor blocker, valsartan, whereas the effect of an adrenergic alpha1 and beta1,2 blocker, carvedilol, was borderline. Survival rate in the PAH rats was significantly improved when they were treated with valsartan or carvedilol.
CONCLUSIONS: Upregulated neurohumoral factors seem to play an important role in LV remodeling without mechanical overload, and are associated with impairment of prognosis in rats with PAH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16936438     DOI: 10.1253/circj.70.1208

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  13 in total

Review 1.  Neurohormonal modulation as therapeutic avenue for right ventricular dysfunction in pulmonary artery hypertension: till the dawn, waiting.

Authors:  Roy Emanuel; Astha Chichra; Nirav Patel; Thierry H Le Jemtel; Abhishek Jaiswal
Journal:  Ann Transl Med       Date:  2018-08

Review 2.  Right ventricular adaptation and failure in pulmonary arterial hypertension.

Authors:  John J Ryan; Jessica Huston; Shelby Kutty; Nathan D Hatton; Lindsay Bowman; Lian Tian; Julia E Herr; Amer M Johri; Stephen L Archer
Journal:  Can J Cardiol       Date:  2015-01-29       Impact factor: 5.223

Review 3.  Rodent models of heart failure: an updated review.

Authors:  A C Gomes; I Falcão-Pires; A L Pires; C Brás-Silva; A F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

Review 4.  The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.

Authors:  John J Ryan; Stephen L Archer
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 5.  New trial designs and potential therapies for pulmonary artery hypertension.

Authors:  Mardi Gomberg-Maitland; Todd M Bull; Rajeev Saggar; Robyn J Barst; Amany Elgazayerly; Thomas R Fleming; Friedrich Grimminger; Maurizio Rainisio; Duncan J Stewart; Norman Stockbridge; Carlo Ventura; Ardeschir H Ghofrani; Lewis J Rubin
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

6.  Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.

Authors:  Bradley A Maron; Ying-Yi Zhang; Kevin White; Stephen Y Chan; Diane E Handy; Christopher E Mahoney; Joseph Loscalzo; Jane A Leopold
Journal:  Circulation       Date:  2012-07-11       Impact factor: 29.690

7.  Skeletal muscle mitochondrial dysfunction precedes right ventricular impairment in experimental pulmonary hypertension.

Authors:  Irina Enache; Anne-Laure Charles; Jamal Bouitbir; Fabrice Favret; Joffrey Zoll; Daniel Metzger; Monique Oswald-Mammosser; Bernard Geny; Anne Charloux
Journal:  Mol Cell Biochem       Date:  2012-10-26       Impact factor: 3.396

8.  GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension.

Authors:  Lin Piao; Yong-Hu Fang; Kishan S Parikh; John J Ryan; Karen M D'Souza; Tiju Theccanat; Peter T Toth; Jennifer Pogoriler; Jonathan Paul; Burns C Blaxall; Shahab A Akhter; Stephen L Archer
Journal:  Circulation       Date:  2012-11-02       Impact factor: 29.690

Review 9.  Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.

Authors:  Santiago Reyes; Jasmina Varagic; Sarfaraz Ahmad; Jessica VonCannon; Neal D Kon; Hao Wang; Leanne Groban; Che Ping Cheng; Louis J Dell'Italia; Carlos M Ferrario
Journal:  Curr Hypertens Rep       Date:  2017-02       Impact factor: 5.369

10.  Aberrant gene expression of heparanase in ventricular hypertrophy induced by monocrotaline in rats.

Authors:  Toshina Ishiguro-Oonuma; Masako Suemoto; Muneyoshi Okada; Kazuki Yoshioka; Yukio Hara; Kazuyoshi Hashizume; Keiichiro Kizaki
Journal:  J Vet Med Sci       Date:  2015-12-04       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.